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Abstract
Background: Alzheimer’s Disease (AD) is the most common of the conformational neurodegenerative disorders
characterized by the conversion of a normal biological protein into a b-sheet-rich pathological isoform. In AD the
normal soluble Ab (sAb) forms oligomers and fibrils which assemble into neuritic plaques. The most toxic form of
Ab is thought to be oligomeric. A recent study reveals the cellular prion protein, PrPC, to be a receptor for Ab
oligomers. Ab oligomers suppress LTP signal in murine hippocampal slices but activity remains when pretreated
with the PrP monoclonal anti-PrP antibody, 6D11. We hypothesized that targeting of PrPC to prevent Ab oligomer-
related cognitive deficits is a potentially novel therapeutic approach. APP/PS1 transgenic mice aged 8 months were
intraperitoneally (i.p.) injected with 1 mg 6D11 for 5 days/week for 2 weeks. Two wild-type control groups were
given either the same 6D11 injections or vehicle solution. Additional groups of APP/PS1 transgenic mice were
given either i.p. injections of vehicle solution or the same dose of mouse IgG over the same period. The mice were
then subjected to cognitive behavioral testing using a radial arm maze, over a period of 10 days. At the conclusion
of behavioral testing, animals were sacrificed and brain tissue was analyzed biochemically or
immunohistochemically for the levels of amyloid plaques, PrPC, synaptophysin, Ab40/42 and Ab oligomers.
Results: Behavioral testing showed a marked decrease in errors in 6D11 treated APP/PS1 Tg mice compared with
the non-6D11 treated Tg groups (p < 0.0001). 6D11 treated APP/PS1 Tg mice behaved the same as wild-type
controls indicating a recovery in cognitive learning, even after this short term 6D11 treatment. Brain tissue analysis
from both treated and vehicle treated APP/PS1 groups indicate no significant differences in amyloid plaque
burden, Ab40/42, PrPC or Ab oligomer levels. 6D11 treated APP/PS1 Tg mice had significantly greater
synaptophysin immunoreactivity in the dentate gyrus molecular layer of the hippocampus compared to vehicle
treated APP/PS1 Tg mice (p < 0.05).
Conclusions: Even short term treatment with monoclonal antibodies such as 6D11 or other compounds which
block the binding of Ab oligomers to PrPC can be used to treat cognitive deficits in aged AD transgenic mice.
Background
Alzheimer’s disease is the most common cause of
dementia worldwide, affecting approximately 36 million
people currently [1]. By 2050, according to some esti-
mates, 1 in 85 persons worldwide will be affected by AD
[1,2]. Currently available treatments for AD provide lar-
gely symptomatic relief with only minor effects on the
course of the disease. The diagnostic neuropathological
lesions of AD are the accumulation of Ab as neuritic
plaques and congophilic angiopathy, as well as aggrega-
tion of abnormally phosphorylated tau in the form of
neurofibrillary tangles (NFTs) [3]. The dominant theory
for the causation of AD has been the amyloid cascade
hypothesis [4,5]. This theory currently suggests that
accumulation of Ab peptides particularly in a highly
toxic oligomeric form is the primary pathogenic driver,
that downstream leads to tau hyperphosphorylation,
NFT formation and ultimately to synaptic and neuronal
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loss. A recent study using oligomers derived from syn-
thetic Ab peptides reported that a high affinity specific
binding site for Ab oligomers is the cellular prion pro-
tein (PrPC) and that PrPC is a requirement for acute Ab
oligomer suppression of synaptic plasticity in hippocam-
pal slices [6,7]. Furthermore, it was shown that a mono-
clonal anti-PrP antibody (mAb) 6D11 could block this
Ab oligomer mediated toxicity in hippocampal slices
[6,7]. In addition it was recently shown that PrPC
expression is necessary for memory impairment in an
AD transgenic (Tg) mouse model [8]. However, another
study, while confirming that PrPC is a high affinity bind-
ing site for Ab oligomers, suggested that memory
impairment induced by acute injection of Ab oligomers
derived from synthetic peptides does not require PrPC
[9]. We sought to test the hypothesis that short term
treatment using monoclonal 6D11 could reverse mem-
ory impairment in an established APP/PS1 Tg mouse
model of AD [10]. Such an approach to block in vivo
derived Ab oligomer mediated toxicity would represent
a novel treatment strategy for AD.
Results
Treatment and Behavioral Studies
Cognitive ability was assessed by the number of errors
(entry to previously visited arms) in consuming all 8
rewards using the radial arm maze (Figure 1). Statistical
analysis by two-way ANOVA revealed a significant
treatment effect in Tg 6D11 treated versus vehicle trea-
ted mice (p < 0.0001) with a Bonferroni post-hoc analy-
sis showing no difference between Tg 6D11 treated and
wild-type mice which were injected with either PBS
alone or 6D11. APP/PS1 Tg vehicle treated mice and
APP/PS1 mice treated with mouse IgG made significantly
more errors than wild-type animals and 6D11 treated Tg
mice (p < 0.01). The APP/PS1 Tg groups given vehicle
(phosphate buffered saline [PBS]) or mouse IgG did not
show statistically significant differences.
Immunohistochemical Analyses for Amyloid Burden by
Stereology
Immunohistochemistry of tissue sections revealed no
significant difference in amyloid plaque burden in both
the cortex and hippocampus of 6D11 treated Tg versus
vehicle treated Tg mice using stereological methods
(Figures 2 and 3).
Immunohistochemical Analyses for Synaptic Density
Histological sections showed statistically significant
greater synaptophysin immunoreactivity in the molecu-
lar layer of the dentate gyrus of the hippocampus
among Tg mice treated with 6D11 monoclonal antibody
versus vehicle treated Tg animals (p = 0.0267 by one-
tailed t-test) (Figure 4).
Tissue homogenization and sandwich ELISA for Ab levels
ELISA results for 6D11 treated Tg versus vehicle treated
Tg mice revealed no significant differences in Ab levels
for either formic acid (FA) treated (total Ab fraction) or
diethylamine (DEA) treated (soluble Ab fraction) brain
homogenates by two tailed t-test (Figure 5). Analysis of
plaque-associated amyloid-b levels in FA treated
Figure 1 Radial Arm Maze Cognitive Testing. Figure 1 shows the results of radial arm maze cognitive testing. The number of errors is plotted
versus the day of testing. Two-way ANOVA revealed a significant treatment effect in Tg 6D11 treated (n = 10) versus vehicle treated (n = 8) or
murine IgG treated (n = 9) APP/PS1 Tg mice (p < 0.0001) with a Bonferroni post-hoc analysis showing no difference between Tg 6D11 treated
and wild-type mice which were injected with either PBS alone (n = 8) or 6D11 (n = 9). APP/PS1 Tg non-treated mice and APP/PS1 mice treated
with mouse IgG made significantly more errors than wild-type animals and 6D11 treated Tg mice (p < 0.01).
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homogenates presented similar levels in both Tg
mouse groups for both Ab40 and Ab42. DEA treat-
ment extraction of non-plaque associated soluble Ab
from prepared homogenates also showed comparable
levels of soluble Ab40 or Ab42. There was a slight
trend toward lowered Ab40/42 levels in FA-treated
brain homogenates, and raised Ab40/42 levels in DEA-
treated brain homogenates for 6D11 treated Tg ani-
mals; however, the differences were not statistically
significant.
Figure 2 Bar Graphs of Amyloid Quantitation by Stereology. A and B shows a bar graphs of the amyloid quantitation by stereology in the
cortex (A) and hippocampus (B) of Tg vehicle injected (n = 8) and 6D11 treated Tg mice (n = 10). There were no significant differences in the
amyloid burden (% area occupied by 6E10 immunoreactivity) in both the cortex and hippocampus.
Figure 3 Representative Sections Immunostained with anti-Ab Antibody. A-D show representative immunostained sections with anti-Ab
antibody 6E10 in the cortex and hippocampus at low power (A and B) and in the cortex (C and D) at higher magnification of 6D11 treated Tg
mice (A and C) and vehicle injected Tg mice (B and D). Scale bar = 200 μm for A and B. Scale bar = 50 μm for C and D.
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Western blot detection and quantification of Ab
oligomers and aggregated Ab
Levels of Ab oligomers in brain homogenates of 6D11
treated Tg versus vehicle treated Tg mice were detected
by oligomer-specific polyclonal antibody, A11 [11]
(Figure 6A. left), and then subjected to densitometric
analysis. Semiquantitation of A11 immunoreactive oli-
gomers (~55 kDa) shows no significant difference
between the groups (Figure 6B). The specificity of A11
blotting was confirmed by stripping the membrane and
probing with anti-Ab 6E10 monoclonal antibody [12]
(Figure 6A, right). There were no significant differ-
ences in the levels of aggregated Ab peptides in 6D11
treated versus vehicle treated Tg mice as determined
by ELISA (Figure 6C).
Western Blot Detection and Quantification of PrPC
Semiquantitative analysis for areas under the curves
representing di-, mono-, and non-glycosylated bands of
PrPC were similar among all three groups (Figure 7).
Two-way ANOVA analysis showed no significant differ-
ences between 6D11 treated Tg, vehicle treated Tg and
wild type control mice for all isoforms of PrPC.
Discussion
We demonstrate that short term administration of anti-
PrP mAb 6D11 is able to reverse cognitive deficits in an
AD Tg mouse model, as determined by radial arm maze
testing. Previous studies have shown that Ab oligomers
made from synthetic Ab peptides bind to PrPC and sup-
pression of LTP in mouse hippocampal slice cultures
could be abrogated by mAb 6D11, due to blocking the
binding of oligomers to PrPC [6]. In addition a recent
study has shown that expression of PrPC is required for
the manifestation of cognitive deficits in an APP/PS1 Tg
mouse model of AD, as determined by Morris water
maze testing [8]. In this study APP/PS1 Tg mice were
crossed onto a PrPC knock-out (KO) background and it
was found that these mice behaved similarly to wild-
type mice despite having equivalent Ab and amyloid b
precursor protein (APP) levels to APP/PS1 Tg mice
expressing PrPC [8]. In the current study we show that
just two weeks of treatment with 6D11 in vivo can have
major cognitive benefits. It is important that this effect
occurs without any significant change in the amyloid
burden or Ab peptide levels, determined by stereological
and biochemical methods. This is not surprising since
Figure 4 Quantitation of Synaptophysin Immunoreactivity. A shows a bar graph representation of synaptophysin immunoreactive
presynaptic terminals in the molecular layer of the dentate gyrus of the hippocampus. The differences between 6D11 treated Tg mice (n = 10)
and vehicle treated Tg mice (n = 8) are statistically significant by one-tailed t-test (p = 0.0267). B-E show representative sections immunostained
with anti-synaptophysin antibody in the hippocampus at 10x magnification (B and C- Scale bar = 100 μm) and at 100x magnification (D and
E- Scale bar = 10 μm) with the green box indicating the area of molecular layer magnified to the higher power. Images are of representative
6D11 treated Tg mice (B, D) and vehicle treated Tg mice (C, E).
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past studies of amyloid directed therapeutic interven-
tions, such as vaccination, have shown in AD Tg mouse
models that behavioural benefits often do not correlate
with the overall amyloid burden but with Ab oligomer
levels [13-16]. In this study, we also have not altered Ab
oligomer or aggregated Ab levels. The likely mechanism
of action of the behavioural improvement in the 6D11
treated Tg mice is by blocking the binding of Ab oligo-
mers to PrPC. This is consistent with a critical role of
PrPC for mediating Ab oligomer toxicity. Importantly
we show using unbiased stereology that the 6D11 treat-
ment in the APP/PS1 Tg mice was associated with
greater synaptophysin immunoreactivity in the hippo-
campus compared to vehicle treated Tg mice. Hence
6D11 treatment ameliorated loss of synaptophsin immu-
noreactivity. Synaptic loss is a hallmark of AD which
correlates best with the cognitive status of patients, as
demonstrated in many studies using immunoreactivity
of the presynaptic marker, synaptophysin [17,18].
Reduced synaptophysin immunoreactivity has also been
detected in APP/PS1 Tg mouse models, which can be
prevented by Ab plaque and Ab oligomer reducing
interventions such as immunotherapy [19,20]. It is likely
that the behavioural rescue in the 6D11 treated APP/
PS1 mice is related to a greater synaptic density com-
pared to Tg controls, as quantitated by synaptophysin
immunoreactivity.
It has been suggested that PrPC may be capable of
binding other oligomeric species and function physiolo-
gically as a general “aggregation receptor” [21]. If this is
true, application of mAbs such as 6D11 or other com-
pounds which block oligomer binding to PrPC at the
6D11 epitope (residues 93 to 109 [22]) could have thera-
peutic effects for a range of neurodegenerative confor-
mational disorders. Interestingly, we have recently
shown that 6D11 is therapeutically active in vitro and in
vivo for prion disease using tissue culture and mouse
models of prion infection [23,24]. Prion infection is
dependent on binding between PrPC and PrPSc, with
transmission of the abnormal conformation to the normal
PrPC. The 6D11 epitope is important for this interaction
[23], with PrPSc having an abnormal conformation with
high b-sheet content similar to Ab oligomers. Monoclonal
antibodies with epitopes to all the different regions of
PrPC have been screened for inhibition of prion infection
[25,26]. Of the few anti-PrP mAbs with therapeutic activ-
ity, several of these have an epitope at or near the 6D11
epitope [25], highlighting the importance of this region of
Figure 5 Ab40/42 Quantitation Biochemically. Shows the levels of Ab40 and Ab42 in the FA and DEA extracted material from brains of
vehicle treated Tg (n = 8) and 6D11 treated Tg mice (n = 10). Levels from the FA extract fraction of Ab40 and Ab42 are shown in A and B,
respectively. Levels from the DEA extract fraction of Ab40 and Ab42 are shown in C and D, respectively. There were no significant differences in
the levels of Ab40 or Ab42 in either the FA or DEA fractions.
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PrPC for binding to protein structures with an abnormal
b-sheet conformation.
A recent study suggested that PrPC is not essential for
Ab oligomer related toxicity, while confirming the high
affinity binding between Ab oligomers and PrPC [9].
This study used very different methods from what is
reported here. In the latter study mice which did not
have any AD related pathology from human transgene
expression were injected directly into brain ventricles
using Ab oligomers derived from synthetic Ab peptides.
This represents a sub-optimal animal model for AD
pathology [20,27]. Furthermore, what represents a biolo-
gically relevant Ab oligomer preparation is a subject of
some debate with Ab peptide assemblies ranging in
mass from dimers up to multimers of ~1 MDa having
been reported as neurotoxins using in vitro assays
[28-32]. In our study we demonstrate blocking of cogni-
tive deficits related to in vivo generated Ab oligomers.
The Balducci et al. studies also used novel object recog-
nition testing in contrast to radial arm maze or water
maze spatial memory testing [9]. Most behavioural stu-
dies using AD Tg models examine spatial memory with
radial or water maze testing [20,27], with some studies
in AD Tg mice having shown impairments of spatial
memory but not of object recognition [33]. In our own
past studies of behaviour where we have used novel
object recognition in AD Tg mice, this has been a less
sensitive measure that is more open to confounding
variables [16,34]. Hence, these significant methodologi-
cal differences likely explain the contrasting results. In
addition, the recent report that crossing an APP/PS1 Tg
mouse onto a PrPC KO rescues the mice from any cog-
nitive deficit, despite there being no change to the Ab
or amyloid precursor protein levels, clearly points to the
importance of PrPC in mediating Ab related toxicity [8].
Our findings are consistent with this report, which also
showed that the synaptic density in the APP/PS1 Tg mice
on a PrP KO background was greater compared to con-
trols, using synaptophysin immunoreactivity. However,
this is a controversial and complex area of research, since
it is likely that Ab oligomers mediate toxicity via multiple,
non-mutually exclusive pathways and the results obtained
depend on the experimental setting [35-37].
In our study we used very large doses of 6D11. This
was because only a small fraction of peripherally
injected mAb would be expected to cross the blood
brain barrier (BBB). Prior studies have established that
about ~0.1% of the injected dose of IgG anti-Ab
Figure 6 Quantitation of Ab Oligomer and Aggregated Ab Levels. A shows a Western blot using Ab oligomer specific antibody A11 on the
left from each of two representative 6D11 treated and vehicle treated Tg mice. On the right, a Western blot using anti-Ab monoclonal antibody
6E10 is shown. B shows a bar graph of the densitometric analysis of the major A11 immunoreactive band at ~55 kDa, in arbitrary O.D. units. C
shows a bar graph of the levels of aggregated Ab in 6D11 treated (n = 10) and vehicle treated Tg mice (n = 8) as determined by ELISA. There is
no significant difference between the 6D11 treated and vehicle treated Tg mice in the levels of Ab oligomers determined by Western blot or of
aggregated Ab determined by ELISA.
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antibodies cross the BBB and that this small faction can
have a significant biological effect [38-40]. We presume
that a similar percentage of our 6D11 was also able to
cross the BBB. We controlled for possible non-specific
effects on behaviour of injecting such large doses of
6D11 or murine IgG by including a group of APP/PS1
mice which were injected with an equivalent dose of
murine IgG and a group of wild-type mice injected with
the same dose of 6D11. The APP/PS1 Tg mice given
the murine IgG performed similarly on the radial arm
maze to the Tg mice given vehicle, while the 6D11
injections had no demonstrable behavioural effect in the
wild-type mice compared to wild-type mice given vehi-
cle injections. Future development of single chain vari-
able region (scFv) antibodies based on 6D11 or
peptidomimetics which also block Ab oligomer binding
to PrPC at the 6D11 epitope, may lead to agents which
are even more effective and have better pharmacokinetic
properties. However, it is striking that a relatively short
term administration of 6D11 over a period of 2 weeks
was able to reverse behavioural deficits associated with a
high amyloid burden and high Ab40/42 levels. This sug-
gests the significant potential for blocking the PrPC-Ab
oligomer interaction as a therapeutic intervention in
pre-existing AD. This is in contrast to approaches such
as vaccination, which are in current clinical trials [41].
Immunomodulation has been shown in AD Tg mouse
studies to be much less effective or ineffective with
more advanced disease [16] and in more limited studies
in AD patients amyloid removal has not been associated
with any significant cognitive benefits [42,43]. The lim-
ited autopsy data from the initial human active
Figure 7 Quantitation of PrPC Levels. A shows representative Western blots using anti-PrP mAb 6D11 showing immunostainging bands
corresponding to the non-, mono-, and diglycosylated isoforms of PrPC from a Tg 6D11 treated Tg mouse, vehicle treated Tg mouse and a
wild-type mouse. B depicts a bar graph of the densitometric analysis (in arbitrary units) of the non-, mono-, and diglycosylated PrPC bands. There
are no significant differences the mouse groups in the levels of PrPC.
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vaccination trial targeting fibrillar Ab plaque deposits
showed that patients had partial or near complete pla-
que removal and a reduction of Ab load compared to
age matched non-immunized controls. However, there
were no differences between placebo and active immu-
nization groups in the long-term survival outcome, time
to severe dementia and in cognitive outcome measure-
ments such as ADAS-Cog, MMSE or DAD [42]. In liv-
ing patients, part of a passive immunization trial
targeting Ab, a 25% amyloid reduction versus controls
was documented using PET imaging methods, in the
absence of measurable cognitive benefits [43]. These
studies highlight the importance of developing interven-
tions which directly target Ab oligomers or downstream
toxicity related to Ab oligomer interactions, such as the
approach described here.
Conclusions
We demonstrate in an AD Tg mouse model that infu-
sion of an anti-PrPC mAb, produces a significant beha-
vioural rescue in the setting of advanced disease, even
with a relatively short treatment regiment. We presume
the mechanism of action is by blocking the binding
between Ab oligomers and PrPC, resulting in an ameli-
oration of synaptic loss. This finding opens a novel
therapeutic approach for AD and perhaps for other con-
formational neurodegenerative disorders.
Methods
Treatment of APP/PS1 Tg Mice
APP/PS1 Tg mice [10] aged 8 months were either trea-
ted with anti-PrP monoclonal antibody 6D11 (n = 10)
or given phosphate-buffered saline (PBS) (n = 8) or
given mouse IgG (n = 9). These APP/PS1 Tg mice carry
a Swedish K670L/M671L APP mutation and a presenilin
1 M146L mutation [10]. By 8 months of age these APP/
PS1 Tg mice already have abundant Ab deposition in
the form of plaques [10]. 6D11 is an anti-PrP mouse
monoclonal antibody (mAb) which recognizes residues
93 to 109 of mouse PrPC with residues 97 to 100 being
the primary determinant for binding [22]. This region of
PrPC is very homologous in human PrPC; hence, 6D11
also recognizes human PrPC [23]. Wild-type mice were
given PBS i.p. or the same dose of 6D11 as controls.
Treatments consisted of 1 mg injections 5 times a week
for 2 weeks of either the 6D11 or mouse IgG (Invitro-
gen, catalogue number 10400C). The mouse IgG was
dialyzed against PBS prior to in vivo use in order to
remove the sodium azide in which it was supplied. Tg
6D11 treated (n = 10), Tg mouse IgG treated (n = 9),
Tg PBS injected (n = 8), wild-type 6D11 treated (n = 9)
and wild-type PBS control mice (n = 8) were subjected
to behavioural testing by radial arm maze to assess
the effect of 6D11 treatment on cognition by spatial
learning. The 6D11 or control injections continued dur-
ing the behavioural analysis. All mouse care and experi-
mental procedures were approved by the Institutional
Animal Care and Use Committee at the New York Uni-
versity School of Medicine.
Behavioural Analyses
Spatial learning (working memory) was evaluated using
an eight-arm radial maze with a water well at the end of
each arm, as we have previously reported [15,44,45].
Clear Plexiglas guillotine doors, operated by a remote
pulley system, controlled access to the arms from a cen-
tral area from which the animals entered and exited the
apparatus. After 2 days of adaptation, water-restricted
mice (2 h daily access to water) were given one training
session per day for ten consecutive days. For each ses-
sion, all arms were baited with 0.1% saccharine solution,
and animals were permitted to enter all arms until the
eight rewards had been consumed. The number of
errors (entries to previously visited arms) and time to
complete each session were recorded. The behavioral
testing was performed by an individual blinded to the
animal’s treatment status.
Immunohistochemical Analyses for Amyloid Burden
Mice were anesthetized with sodium pentobarbital (150
mg/kg i.p.) and perfused transaortically with heparinized
phosphate buffered-saline, and the brains processed.
The right hemisphere was immersion-fixed in periodate-
lysine-paraformaldehyde, while the left hemisphere was
snap frozen for measurements of Ab40/42 peptide, PrPC
and Ab oligomer levels. After fixation, brains were
placed in 2% DMSO/20% glycerol in PBS and stored
until sectioned. Serial coronal sections of 40 μm were
cut and every fifth section stained with 6E10, a mono-
clonal antibody that recognizes Ab and immunolabels
both pre-amyloid and Ab plaques as we have previously
described [34,45]. Sections were incubated in 6E10 at a
1:1000 dilution and anti-synaptophysin SY38 at a 1:2000
dilution (Millipore, MA). A mouse-on-mouse immuno-
detection kit (Vector Laboratories, Burlingame, CA) was
used with the anti-mouse IgG secondary antibody at a
1:3000 dilution. Antibody staining was revealed with
3,3’-diaminobenzidine tetrahydrochloride (DAB, Sigma-
Aldrich) with nickel ammonium sulfate (Ni; Mallinck-
rodt, Paris, KY) intensification.
Image Analyses for Amyloid Burden and Synaptophysin
Immunoreactivity
Immunohistochemistry of tissue sections was quantified
with a Bioquant image analysis system (BIOQUANT
Image Analysis Corporation, Nashville, TN), and
unbiased sampling was used, as previously published
[44,45]. Seven sections were analyzed per animal. All
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procedures were performed by an individual blinded to
the experimental condition of the study. Total A[001]
burden (defined as the percentage of test area occupied
by Ab) was quantified for the cortex and for the hippo-
campus on coronal plane sections stained with the
monoclonal antibody 6E10. Intensification with nickel
ammonium sulfate resulted in black Ab with minimal
background staining that facilitated threshold detection.
The cortical area was dorsomedial from the cingulate
cortex and extended ventrolaterally to the rhinal fissure
within the right hemisphere. Test areas (640[001] μm ×
480 μm) were randomly selected by applying a grid (800
μm × 800 μm) over the traced contour. Hippocampal
measurements (600 μm × 600 μm) were performed
similarly to the cortical analysis [34,44]. Synaptophysin
positive presynaptic terminals were counted bilaterally
in the molecular layer of the dentate gyrus of the hippo-
campus using a 100× objective of at least three hippo-
campal sections in each mouse comparing the 6D11
treated and PBS injected APP/PS1 Tg mice. The frac-
tional area occupied by the immunoreactive puncta was
measured as previously described using a Bioquant
image analysis system [8,46].
Tissue homogenization and sandwich ELISA for Ab levels
Brain homogenates, 10% (w/v), were prepared in 20
mmol/L Tris, pH 7.4, 250 mmol/L sucrose, 1 mmol/L
EDTA, and 1 mmol/L EGTA. Immediately before
use, 1:100 volume of 100 mmol/L PMSF solution (in
ethanol) and 1:1000 volume of LAP (5 mg each of
leupeptin, antipain, and pepstatin A per milliliter of
N-N-dimethylformamide) was added to the homogeni-
zation buffer, as we have previously described [44,45].
For extraction of soluble Ab, brain homogenates were
thoroughly mixed with an equal volume of 0.4%
diethylamine/100 mmol/L NaCl and centrifugation at
135,000 × g for 1 hr at 4 °C and subsequently neutra-
lized with 1:10 volume of 0.5 mol/L Tris, pH 6.8, fol-
lowed by aliquoting, flash-freezing on dry ice, and
storage at -80°C until analysis. Samples were also trea-
ted with formic acid (95%, Sigma) for extraction of
total Ab. Homogenates (200 μl) were added to 440 μl
cold formic acid (FA) and sonicated for one minute on
ice. Subsequently, 400 μl of this solution was spun at
100,000 × g for 1 hour at 4 °C. Then, 210 μl of the
resulting supernatant was diluted into 4 ml of FA neu-
tralization solution (1 M Tris base, 0.5 M Na2HPO4,
0.05% NaN3), aliquoted, flash-frozen on dry ice and
stored at -80°C until used for Ab measurements.
The total and soluble Ab levels were measured using a
combination of mouse monoclonal antibody 6E10 (spe-
cific to an epitope present on amino acid residues 1 to
16 of Ab) and two different rabbit polyclonal antibodies
specific for either Ab40 (R162) or Ab42 (R165), in a
double-antibody sandwich ELISA as described pre-
viously [44,45]. The optical density (OD) was measured
at 450 nm. The relationship between OD and Ab pep-
tide concentration was determined by a four-parameter
logistic log function. Non-linear curve fitting was per-
formed with the KinetiCalc program (Biotek Instru-
ments, Inc., Winooski, VT) to convert OD of plasma to
estimated concentrations. The assay was performed by
an investigator (PM) blinded to group assignment. The
levels of Ab species are presented as μg of Ab per g of
wet brain, taking into account dilution factors intro-
duced by multiple steps throughout the assay (brain
homogenization and extraction procedures).
Western Blot Detection and Quantification of Ab
Oligomers
Samples of brain homogenate were centrifuged at
100,000 × g for 1 hour, and the total protein concentra-
tion in the supernatant was estimated by using the
Bicinchoninic acid assay (BCA; Pierce, Rockford, IL), as
we have previously described [44,45]. Samples (40 μg of
total protein), mixed with an equal volume of Tricine
sample buffer, were electrophoresed on 12.5% Tris-
tricine polyacrylamide gels (under nonreducing condi-
tions) and transferred to nitrocellulose membranes. The
blots were blocked with 5% nonfat dry milk in Tris-
buffered saline Tween 20 (TBS-T) for 2 hours at room
temperature. Oligomer-specific A11 polyclonal antibody
(Biosource, Camarillo, CA) was diluted (1:1000) in 0.1%
BSA/TBS-T and incubated with the blots for 2 h at
room temperature. Bound antibody was visualized with
horseradish peroxidase-conjugated goat anti-rabbit IgG
(1:8000; 1 h, Pierce, Rockford, IL) and the ECL detection
system (Pierce, Rockford, IL). The specificity of A11
staining was confirmed by probing the membrane with
anti-Ab monoclonal antibodies 6E10 or 4G8 [44]. Densi-
tometric analysis of A11 immunoreactive oligomer spe-
cific bands was performed with NIH Image J version
1.34 software.
Western Blot Detection and Quantification of PrPC
Brain samples were weighed, homogenized and soni-
cated (10% w/v) in a buffer containing 20 mM Tris pH
7.5, 250 mM sucrose, 1 mM EDTA, 1 mM EGTA, and
Complete® protease inhibitor (Boehringer-Mannheim,
Indianapolis IN). Samples were centrifuged for 3 min at
10,000 × g at 4°C to remove cellular debris. The total
protein concentration was assayed by the BCA method
as described above. If not used immediately, superna-
tants were divided into 100 μl aliquots, which were flash
frozen and stored at -80°C. Semi-quantitative Western-
blot was used to compare the relative content of PrPC
among samples containing matched amounts of total
protein. Aliquots of brain homogenates containing 20
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μg of the total proteins were titrated by adding sample
buffer to a final protein concentration of 1 μg/1 μl.
Samples were subjected to SDS-PAGE and Western-
blotting into nitrocellulose membranes where PrPC was
detected with Mab 6D11 (0.05 μg/ml) as described pre-
viously [23]. For the densitometric analysis, the exposure
time of Western blot membranes was kept standard in
all experiments at 30 seconds. Developed films were
converted into 8 bit grayscale digital files using a Epson
Perfection 4990 scanner (Epson America; Long Beach,
CA) and Adobe Photoshop software 7.01 (Adobe Sys-
tems; San Jose, CA) and saved in a TIF format with a
resolution of 600 dpi. Quantification of PrPC was per-
formed using NIH Image J software v 1.34. Areas under
the curves for three PrPC bands representing non-,
mono-, and diglycosylated isoforms of the protein were
analyzed from each sample.
Sandwich ELISA for Aggregated Ab
Aggregated Ab levels were determined using an Invitro-
gen Aggregated Ab kit which uses a solid phase sand-
wich ELISA (Invitrogen, Camarillo, CA). This was done
following the manufacturer’s instructions. In brief, a
monoclonal antibody specific for the N-terminus of
human Ab was pre-coated onto wells of the provided
microtiter strips. Samples diluted in the provided stan-
dard diluent buffer were measured against a standard
containing aggregated Ab. Samples were incubated for 2
hrs at room temperature allowing the Ab to bind the
capture antibody, followed by extensive washing. Incu-
bation with biotinylated detector antibody (same mono-
clonal antibody coated onto wells) for 1 hr at RT served
as a detection antibody by binding to the immobilized
aggregated Ab. After removal of excess antibody, horse-
radish peroxidase-labelled streptavidin (SAV-HRP) was
allowed to incubate for 30 min, followed by washing,
after which tetramethylbenzidine (TMB) substrate was
added to produce a colorimetric solution. The TMB
reaction was stopped and the absorbance of each well
was read at 450 nm. The standards provided a linear
curve and the best-fit line determined by linear regres-
sion was used to calculate the concentration of aggre-
gated Ab in samples.
Data Analysis
The amyloid burden, the levels of Ab40/42 peptides within
the brain, Ab oligomers and aggregated Ab levels were
analyzed by unpaired two-tailed Student’s t-tests (Graph-
Pad Prism, version 5; GraphPad Inc., San Diego, CA,
USA). The synaptophysin immunoreactivity was compared
by one-tailed Student’s t-test (GraphPad Prism). The radial
arm maze data was analyzed by two-way ANOVA
repeated measures and a Bonferroni post hoc test
(GraphPad Prism). The PrPC band densitometry was also
analyzed by two-way ANOVA (GraphPad Prism).
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